Kamada Ltd. (NASDAQ:KMDA – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.39 and traded as low as $5.31. Kamada shares last traded at $5.34, with a volume of 19,941 shares trading hands.
Wall Street Analysts Forecast Growth
KMDA has been the subject of a number of research analyst reports. StockNews.com downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, August 15th. Finally, Stifel Nicolaus started coverage on shares of Kamada in a research report on Wednesday, July 3rd. They set a “buy” rating and a $18.00 price target for the company.
Check Out Our Latest Research Report on Kamada
Kamada Trading Down 0.7 %
Kamada (NASDAQ:KMDA – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Kamada had a return on equity of 6.15% and a net margin of 9.75%. The business had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $39.70 million. As a group, research analysts forecast that Kamada Ltd. will post 0.26 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Kamada stock. Vanguard Group Inc. grew its stake in Kamada Ltd. (NASDAQ:KMDA – Free Report) by 8.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,325,026 shares of the biotechnology company’s stock after purchasing an additional 100,800 shares during the quarter. Vanguard Group Inc. owned approximately 2.31% of Kamada worth $7,433,000 as of its most recent filing with the SEC. 20.38% of the stock is owned by institutional investors.
Kamada Company Profile
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Further Reading
- Five stocks we like better than Kamada
- What is a Bond Market Holiday? How to Invest and Trade
- Texas Roadhouse Stock Steering for New Highs This Year
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Stock Average Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.